Cytodyn Inc (CYDY)

[HyGro]

"superiority over Standard Of Care..in EVERY trial it has participated in." Not true. CoV failed to even show superiority to saline solution -- failed the CD10, CD12 and the Long CoV ("directional" results). HIV combo results are not as good as Gilead's capsid inhibitor (LL 81% vs 81-95% efficacy). Then NASH 305 mg had fat reduction (MDFF) of 16-20% when Madrigal's data was 48% for ~similar time period. GvHD -- Cytodyn gave up.

mTNBC analysis can't be compared the way CyDy did -- combing naive trial patients and heavily treated R/R patients -- can't compare to Trovaldy's super heavily treated R/R. It got the SEC/DOJ investigating the invalid comparison.

So bottomline. LL doesn't show commercial superiority in any indication.